

## Twitter Thread by Stefan Kertesz, MD



**Stefan Kertesz, MD**

@StefanKertesz



1/I'm excited that Dr. @AjayManhapra is presenting on concerns about mandatory opioid taper for VA's MAT-VA journal club, based on our shared paper... he notes Human costs of mandatory and widespread opioid taper


Human cost of policies- patient stories emerge



2/He cites @BethDarnall as the best available study, noting that even when one offers the best support system, a significant % of patients do not have a reduction in pain or pain worsens.

# Opioid tapering: Assumptions Vs reality!


Observational data



Harden et. al Pain Medicine 2015

Clinical trial data

Figure. Change in Opioid Morphine Equivalent Daily Dose and Absolute Change in Pain Intensity Score From Baseline to Month 4 for Study Completers



NRS indicates numeric rating scale.


Darnall et, al. JAMA Int. Med. 2018

3/In a way that will seem controversial, he proposes that opioid therapy is not exactly an analgesic. This is daily use of an addictive substance that offers relief, where only a minority develop addiction.

4/I should caution that [@AjayManhapra](#) is far from a "fan" of opioids for pain. Many people on them do not get benefit, he says. My reading of same data is more favorably disposed, even though we collaborate

5/There is an "opponent effect" so that relief from opioids is also opposed - not in all people and to the same degree - but this is part of the dependence dilemma for some persons at high dose


Allostatic opponent process =  
Escalating baseline pain + declining relief + increasing opioid need



Manhapa, Arias, Ballantyne, Substance Abuse 2017; Adapted from Solomon HL Am. Psych. 1980

6/Trigger warning: Dr. Manhapa describes a distinct category of Opioid Use Disorder (which most patients do not have at all) from what he and some others call Complex Persistent Opioid Dependence

Complex persistent opioid dependence: Entry at withdrawal/negative affect stage without progression to binge intoxication stage



Ballantyne, Koob et. al Pain 2019

Koob & Le Moal 2008

6/Opioid tapering is intuitively appealing but the goals of a taper are rarely declared and when they are (see below) they are not regularly achieved

# What is a clinically successful tapering?!!

- Is it just achievement of dose reduction?!!
- Successful only if risk improvement can be balanced with goals that are important to patient:
  - Stability or improvement in pain and function
  - Avoiding instability and harm related to medical, psychiatric, and psychological conditions
  - Avoid significant protracted abstinence syndrome
- These goals are not automatically achieved with tapering

DoD/VA Chronic pain guidelines 2010, Manhapra et. al. SAJ 2017

7/The available data on opioid taper suggests (with low confidence) improvement if patients are in "intensive multimodal pain interventions".

And "none of these (tapering) studies showed functional improvement" says [@AjayManhapra](#)

## Opioid tapering: Benefit Vs. Risk- Evidence

### REVIEWS

#### **Benefits and Harms of Long-term Opioid Dose Reduction or Discontinuation in Patients with Chronic Pain: a Rapid Review**

*Katherine Mackey, MD, MPP, Johanna Anderson, MPH, Donald Bourne, MPH, Emilie Chen, BS, and Kim Peterson, MS*

JGIM



J Gen Intern Med 35(Suppl 3):S935–S44


- .. Improvements in mean pain scores were common among patients tapering opioids while participating in intensive multimodal pain interventions and mostly unchanged with less intensive or nonspecific co-interventions.
- Our confidence in these findings is low due to methodological limitations

8/As Dr. Manhapa summarizes, regarding opioid taper

"There is no clear benefit but there are reports of harm"

9/Dose and risk of harm are correlated, but it's complicated. "It's not the opioids alone" - the risk is determined by what else is going on in their lives, personal characteristics. Dose is a MINOR factor in the modeled risk in Veterans Administration

10/Most overdose happens at low dose- so focus on dose is not solid. Veterans Affairs overdose data.



11/Even with heroin/fentanyl, the deaths are polypharmacy often with LOW dose of heroin!

# Most overdoses are “underdoses”

## Heroin overdose

Shane Darke

National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, Australia

“...most ‘overdose’ deaths involved low morphine concentrations, that most overdoses involve polypharmacy, ...”


12/Opioid cessation associated with increased risk of overdose/suicide in Veterans. It's highest in the first month afterward. Then begins to fall. But it never comes down to the level of the persons who were continued on opioids.

<https://t.co/HdjgNhuiHN>

## Opioid cessation and risk of OD/suicide deaths

- All VA patients on opioids in FY2013 followed till end of FY 2014
- Stopping opioids was ass. with increased risk of OD/Suicide death
- Regardless of length of use
- Longer use- higher risk
- Risk increased immediately after stopping opioids, then decreases over 3-12 months.

Oliva, Bowe, Manhapra, Kertesz,... Gordon et. al BMJ 2020





13/Also all cause mortality was elevated after long term opioid therapy interruption in a VA HIV cohort (VACS). Note Dr. Manhapra (like me) is pointing out a fact pattern and NOT arguing every death is Cause and Effect. Humility is called for

## All cause mortality risk also increased with LTOT interruption

- Matched VA Cohort of people with and without HIV and on LTOT
- Mean follow up of 8 years
- 22,996 patients, and 23% died
  - 12% of the deaths were unnatural (6% OD)
- Dose dependent increased risk of all-cause mortality with LTOT in addition to OD and unnatural death
- 60-day opioid prescription interruption ass. w/ increased risk for
  - All cause mortality- HR = 2.63 (2.3933, 2.89),
  - Unnatural death- HR= 1.80 (1.39, 2.33)
  - Overdose- HR= 1.88 (1.29, 2.74)

*Gordon, Manhapra et. al. DAD 2020*

14/In pursuing this discussion I want to highlight issues that we understand are subject to immense dispute because the underlying data are themselves either do not exist or are quite poor

15/If a patient is stable and ostensibly at a higher level of risk for adverse effects from opioids they receive, would reduction of dose make them safer, if they \*consented for that personally\*? We are aware of \*no evidence\* although I think it's totally reasonable to discuss

16/If a patient has shown higher-risk problems (like turning up drunk in the ER while also having taken the prescribed opioids, i.e. major overdose risk), do the clinicians make the patient \*safer\* by switching to buprenorphine as a "safer opioid". FYI: this comes up a lot

17/Please note that honest discussion here has a few limitations. First my friends and I (who discuss these matters with in good faith) often do NOT agree. I am still wrestling with what it would mean to adopt concepts put forward by my friend Ajay. He knows that!

18/Sadly, there are also bad-faith discussants who have slung arrows. Usually, from folks who:

- \*don't have frontline primary care experience
- \*don't propose, fund and deliver peer-reviewed research
- \*are paid by law firms
- \*discount experiences of people with lived experience

19/The story should be about the people and the families whose care has been upended in part because of poor science, immodesty, and policymakers addiction to "quick fixes"

#Listen (YES: after 19 tweets in a row, that applies to me too)